After four successful sessions, China International Import Expo (CIIE) has become an important "window" for global new products and technologies to enter the China market. According to the statistics of the Ministry of Commerce, in the first four sessions of China International Import Expo (CIIE), exhibitors released more than 1500 items of new products, new technologies and new services, and the cumulative intentional turnover reached more than 270 billion US dollars.
Taking China International Import Expo (CIIE) as a bridge, in recent years, many multinational companies have continuously deepened local cooperation, accelerated the introduction of innovation, pushed products from "four-leaf clover" to the market, and realized "turning exhibits into commodities". And a series of global cutting-edge innovations have entered the "fast lane" of China.
Multinational enterprises are deeply involved in China market.
The reporter of National Business Daily noticed that among the multinational enterprises participating in the exhibition, many medical and pharmaceutical enterprises ushered in the important anniversary of entering the China market this year. For example, 1992 Siemens Medical, which opened in Shanghai, Medical Da and Thermo Fisher Scientific Shier Technology, which have entered the China market for 40 years.
1992 is the starting point of China's medical system reform. 1992, Shanghai Siemens Medical Devices Co., Ltd. began to operate, which opened the pioneering history of Siemens Medical in China R&D and the production of medical devices for 30 years. Over the past 30 years, Shanghai Siemens Medical Equipment Co., Ltd. has continuously expanded its production line and business. The first CT equipment will be produced from 1992, X-ray equipment will be produced from 2004, and ultrasound equipment will be produced from 2022. Today, its business covers CT, X-ray machine, mobile C-arm, ultrasound, digital medical and automation R&D, as well as manufacturing and customer service. Up to now, the cumulative shipment of medical equipment produced by Shanghai Company has exceeded 40,000 units, making it one of the largest R&D and production bases of Siemens Medical in the world.
While developing its own business, Siemens Medical also pays attention to cultivating high-quality local suppliers. From the initial promotion of the complete localization of parts supply to the continuous attempt to develop parts with higher technical content with local suppliers, the innovation ability of local suppliers will be enhanced, and the competitiveness of local supply chains will be further enhanced. At present, the localization rate of the company's supply chain exceeds 80%.
In June this year, Siemens Medical China announced a brand-new localization strategy of "National Intelligence Creation", which further rooted in China and served China. "From the equipment production at the beginning of its establishment to the independent research and development capability, Shanghai Siemens Medical Devices Co., Ltd. has also ushered in its thirties. Today, the road ahead is clearer-I believe that under the guidance of the localization strategy of "National Intelligence", Shanghai Siemens Medical Devices Co., Ltd. will open another brilliant chapter by upgrading its high-end manufacturing capabilities, enhancing its independent research and development capabilities, and improving the construction of its local supply chain. " Wang Hao, president of Siemens Medical Greater China, said.
In 2022, it also coincides with the 40th anniversary of Thermo Fisher Scientific Shier Technology officially entering China. Since 1982 set up the first sales office in China, Thermo Fisher Scientific Shier Technology has been fighting side by side with fellow travelers in the upstream and downstream of the industry, promoting the ecological construction of local industries, supporting the high-quality development of the country and helping social progress with cutting-edge technology and innovative solutions customized by China. This time, in the 40th anniversary theme exhibition area, China International Import Expo (CIIE) and Thermo Fisher Scientific Shier Technology also described in detail the course of increasing local investment and practicing localization strategy in China for many years.
"The success of China International Import Expo (CIIE) for five consecutive years has demonstrated the strong resilience of China's economy and its huge market scale, and further strengthened the determination of Thermo Fisher Scientific Shier Technology to' take root in China and serve China'." HannPang, President of Thermo Fisher Scientific Shier Technology China, said, "This year marks the 40th anniversary of Thermo Fisher Scientific Shier Technology's official entry into China, and it is also the fifth consecutive time that Thermo Fisher Scientific Shier Technology has participated in China International Import Expo (CIIE). As a global leader in empowering scientific and technological progress, Thermo Fisher Scientific Shier Technology will use this platform to continuously integrate the world's leading scientific and technological achievements and innovations into localization practice, and join hands with the government and partners from all walks of life to jointly promote the ecological construction of local industries and make the world healthier, cleaner and safer. "
China International Import Expo (CIIE) once again ushered in a "new face".
In addition to the enterprises that have been deeply involved in the domestic market for many years and participated in several consecutive exhibitions, this year's China International Import Expo (CIIE) has also ushered in some "new faces". For example, after being split from Merck last year, Organon made its debut at China International Import Expo (CIIE) as an independent operating company. In addition, at the Third China International Import Expo (CIIE) in 2020, Aijian Aesthetics, which was just acquired by AbbVie for $63 billion, was exhibited for the first time; Today, Aijian Aesthetics, together with its parent company AbbVie, appeared at the 5th China International Import Expo (CIIE) to further demonstrate its heavy products and corporate strategy.
Organon will focus on the innovative layout of "full birth cycle" and "full life cycle" of women and their families, and fully display the diversified innovative achievements and solutions in the two business areas of women's health and classic brands.
Oganon's debut at this China International Import Expo (CIIE) is closely related to women's health, including a "fertility-friendly" contraceptive choice-the only approved single subcutaneous implant contraceptive product Elon (implantation of pregnene), a new long-acting ovulation induction needle Elonva(corifollitropinalfa) for assisted reproduction, and an innovative medical device for treating postpartum hemorrhage (002/kloc).
Organon plans to introduce this innovative medical equipment to China as soon as possible, so as to help women and medical staff in China better cope with this serious life-threatening childbirth complication. The booth also showed the "Fertility Friendly Future Community" for the first time. The design concept of the community aims to break through the "last mile" of the central strategy in the community and family, and help women who are willing to give birth to prevent unintended pregnancy, promote family planning and protect national fertility through the "education-evaluation-intervention" reproductive health service model.
In recent years, consumers' demand for medical beauty is increasing, and the medical beauty industry has become one of the hottest tracks in the medical and health industry. In this China International Import Expo (CIIE), in addition to displaying the most cutting-edge innovative products, Aijian Aesthetics will also share the insights and trend research results of the entire medical beauty industry in China, and jointly organize a series of popular science education activities on medical beauty with upstream and downstream partners to help enhance the public's awareness of medical beauty and help build a good medical beauty ecology.
In addition, the shortage of medical and aesthetic professionals has always restricted the development of the industry. "At this year's China International Import Expo (CIIE), we have more measures to promote the cultivation of talents in the industry. We hope to use the China International Import Expo (CIIE) to show the elegance of the medical and beauty industry to all sectors of society and continue to advocate the standardized development of the industry. " Qiu Hanhua, general manager of China Aijian Aesthetics, said that the Shanghai Innovation Center of Aijian Aesthetics has been completed recently, and it is planned to provide 2,500-3,000 trainings for professional medical and aesthetic doctors every year.
China International Import Expo (CIIE) has obvious spillover effect.
In 20 18, Medical University participated in the first China International Import Expo (CIIE) as the only radiotherapy enterprise, and has been participating for five consecutive years. Medtech has become more and more confident in the China market since it witnessed the spillover effect of the platform of China International Import Expo (CIIE) for the first time. On 20 18, the company set up its regional headquarters in Shanghai, and upgraded its role from "exhibitor" to "investor" to accelerate the landing of international cutting-edge radiotherapy technology in China market. In 2022, on the occasion of the 50th anniversary of Medtronic's global distribution and 40th anniversary of its entry into the China market, Medtronic made its fifth appearance at China International Import Expo (CIIE) with the world-leading intelligent solution for precision radiotherapy, and jointly implemented the strategy of "Healthy China 2030" with customers and industry partners.
At this year's China International Import Expo (CIIE), innovative solutions exhibited by Medical University include HarmonyPro, the world's first new generation of intelligent precision radiotherapy solution. Through the comprehensive upgrade of intelligence, whole process and self-adaptation, this product has injected new kinetic energy into the intelligent, accurate and digital development of radiotherapy industry; ElektaStudio is the first integrated image-guided brachytherapy solution in China, which integrates the Flexitron brachytherapy platform of medical university, Oncenter brachytherapy planning system, applicator and ImagingRing mobile CT system, and can realize the whole process of image-guided brachytherapy, such as setting, position verification, treatment plan design and treatment implementation, without moving patients.
In addition, the mobile design is convenient for the equipment to enter any treatment room in the hospital, and it can perform real-time imaging, providing doctors with patient images needed in all aspects of brachytherapy, including high-quality images needed for planning and design, and low-dose imaging for treatment guidance and quality control, which not only saves the link of transporting patients back and forth from the treatment room to the CT room, but also avoids the displacement of the applicator caused by transportation, and improves the treatment accuracy and diagnosis and treatment efficiency.
In addition to the first exhibition of products, ElektaUnity, an integrated radiotherapy system with high-field magnetic vibration accelerator, appeared in the comprehensive exhibition area of Hall 6.2 at this China International Import Expo (CIIE). ElektaUnity subverts the integration of medical linear accelerator and 1.5T high-field magnetic oscillator on the same platform. Through the high-resolution imaging of the magnetic oscillator, the tumor can be tracked in real time, and the treatment plan can be formulated and adjusted online, so as to realize efficient and personalized online adaptive radiotherapy. Since it officially served China patients in April 2020, ElektaUnity has treated more than 65,438+0,000 cancer patients in China so far, which has brought a leading reference for localized clinical diagnosis and treatment, and also means that cancer radiotherapy in China has ushered in a new level and more possibilities.
As an old friend who participated in China International Import Expo (CIIE) for four consecutive years, Boshi Technology has witnessed the development and growth of the "China International Import Expo(CIIE) Covenant" and continued to bear the spillover effect brought by this high-level opening-up platform. Many innovative medical technologies have transformed "exhibits into commodities". Boston Science also ushered in an important breakthrough in local production and research this year. This year, Boston Scientific successfully registered Boston Scientific Medical Technology (Shanghai) Co., Ltd. to further accelerate the local integration in the fields of production, transformation and innovation incubation outside trade.
In July 2020, the Boston Scientific Polaris intravascular ultrasound system was successfully piloted in local production, and the product was officially registered by the State Medical Products Administration in July 2022. In September, 2022, the first Taipei Polaris intravascular ultrasound system rolled off the production line in Pu Jie factory, which marked the official landing of the first localized product produced and supplied by Boston Science in China, and opened a new chapter in the localization of Boston Science in China.
In view of the high incidence of thyroid nodules in China, China R&D team of Boston Science and Technology has developed an ablation tool-"fused wing" disposable RF ablation electrode. In September 2022, this locally developed and locally produced product successfully completed the first thyroid nodule ablation operation and began to benefit China patients. This is the first medical device developed by Boston Scientific in China and produced in China.
Standing on the node of "the first year of localization", Boston Science has brought more than 60 exhibits, nearly half of which are unlisted products in China, covering five major fields: heart health, peripheral vascular health, digestive and respiratory health, urinary health and tumor prevention. A number of innovative products all appeared.
In addition, from 20 19 to 2020, Boehringer Ingelheim's total stroke solution was presented at China International Import Expo (CIIE) for two consecutive years. At the 4th China International Import Expo (CIIE), Boehringer Ingelheim reached a cooperation with Wenjiang District Government of Chengdu to invest in the construction of German Gold Standard Stroke Rehabilitation Center in Chengdu Medical City, Sichuan. Projects include the physical rehabilitation center under the Jida Rehabilitation Line and the Jida Rehabilitation Internet Hospital. The project achieved its first achievement during the 5th China International Import Expo (CIIE), making the concept of "total solution for stroke" a Chinese wind rehabilitation hospital and an Internet rehabilitation hospital, benefiting the people. During the last China International Import Expo (CIIE), the project was selected as the representative case of the spillover effect of China's entry into the China International Import Expo(CIIE) Pavilion in the 20th year of its entry into WTO, and will be displayed in the exhibition area of "exhibitors become investors" at this year's China International Import Expo (CIIE).
Many enterprises pay attention to the goal of "double carbon"
It is worth mentioning that this year, many multinational companies also expressed their concern about the goal of "double carbon".
In 20021year, Thermo Fisher Scientific Shier Technology announced the global carbon emission target of achieving zero net carbon emission by 2050. During the 40 years in China, Thermo Fisher Scientific Shier Technology has been paying close attention to the local ecological health, integrating cutting-edge innovative technologies and overall solutions into local sustainable development practices, and helping to achieve the goal of "peak carbon dioxide emission and carbon neutrality". Taking this opportunity, Thermo Fisher Scientific Shier Technology will release the sustainable development project-the future ecological device "* * * Ecology" at this China International Import Expo (CIIE). As the finale of the 40th anniversary series, the device extracts environmental samples from different locations in Shanghai, and visualizes the micro-system relationships in the samples with the help of the equipment and technology of Thermo Fisher Scientific Shier Science and Life Science Laboratory, thus further arousing the public's concern about sustainable development and ecological health.
Since the establishment of 1885, sustainable development has been an important guiding principle for the integration of Boehringer Ingelheim's development gene. In 20021year, the company officially launched the strategy of "sustainable development from generation to generation", and incorporated all measures to meet health, economic, social and environmental challenges into the global cooperation network, making positive contributions to the establishment of a sustainable world and a healthier future. Boehringer Ingelheim actively promotes the green and low-carbon transformation of the biomedical industry and contributes to the high-quality development of the industry.
At the 5th China International Import Expo (CIIE), from booth design to booth production and construction, Boehringer Ingelheim carried out the concept of green environmental protection and sustainable development to every detail. The main booth is designed and built around the concept of green and sustainable development with the theme of "Tree of Life". The material selection of the booth is based on the 6R concept, following the principle of recycling, using recyclable decorative materials, which not only makes the overall material recycling rate reach 100%, but also minimizes waste and pollutants. At the same time, high-quality acoustic photoelectric equipment with no noise, no reduction and low power consumption is adopted to save energy and reduce consumption. The latest achievements of Boehringer Ingelheim in sustainable development were displayed on the booth, including the first carbon-neutral factory in China pharmaceutical industry certified by authoritative organizations at home and abroad.